AstraZeneca Reports Results of Fasenra in BORA P-III Extension trial for the Treatment of Severe Eosinophilic Asthma

 AstraZeneca Reports Results of Fasenra in BORA P-III Extension trial for the Treatment of Severe Eosinophilic Asthma

AstraZeneca Reports Results of Fasenra in BORA P-III Extension trial for the Treatment of Severe Eosinophilic Asthma

Shots:

  • The BORA P-III trial involves assessing of Fasenra (benralizumab) enrolling patients in ratio (1:1) who have completed one of the two SIROCCO or CALIMA P-III trials, administering Fasenra 30 mg SC q4w or q8w
  • BORA results (N= 1926): improvement in efficacy outcomes; overall annual asthma exacerbation rate (eosinophil counts of 300 cells per μL) is consistent; 74% of patients with (eosinophil counts ≥300 cells per μL) resulted in exacerbation free
  • AstraZeneca’s Fasenra is a first respiratory biologic, approved in the US, EU including Japan and other countries as an add-on treatment in severe eosinophilic Asthma. It is available as FD SC injection with a prefilled syringe administered q4w for the first three doses followed by q8w

Click here to read full press release/ article | Ref: AstraZeneca | Image: AZ_Baltimore Sun

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post